menu
    • menu
    [{"orgOrder":0,"company":"Currax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Currax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Currax \/ Not Applicable"},{"orgOrder":0,"company":"Currax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone Hydrochloride","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Currax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Currax \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Currax

    Menu

    Currax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Currax

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Currax

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Contrave®/Mysimba® Demonstrates No Increased Risk in Major Adverse Cardiac Events in A Large, Long-Term Real...

                            Details : Contrave, also marketed as Mysimba is an extended release fixed dose combination of naltrexone HCL/bupropion HCL indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.

                            Brand Name : Contrave

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 18, 2023

                            Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Currax

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Currax

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Currax Pharmaceuticals Granted Type C Meeting with FDA Regarding its Phase 3 Study to Evaluate the Safety and ...

                            Details : CX-101 is an investigational drug that is being studied for smoking cessation.The Phase 3 program builds on the successful Phase 2b findings and evaluates a mixed-weight population at a fixed-dose combination of CX-101 (naltrexone/bupropion 32 mg/360 mg ...

                            Brand Name : CX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 21, 2021

                            Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth